# MEDX HEALTH CORP.

## MATERIAL CHANGE REPORT

#### FORM 51-102F3

#### 1. NAME AND ADDRESS OF COMPANY

MedX Health Corp. (the "Company") 220 Superior Boulevard Mississauga ON L5T 2L2

## 2. DATE OF MATERIAL CHANGE

April 12, 2013.

## 3. NEWS RELEASE

The attached news release was issued on behalf of the Company on April 12, 2013, disseminated through news services and filed on SEDAR.

## 4. SUMMARY OF MATERIAL CHANGE

The Company anticipates that it will not be in a position to file its annual audited consolidated financial statements (and related management's discussion and analysis and certifications) for the year ended December 31, 2012, on a timely basis as prescribed by Canadian securities laws.

# 5. FULL DESCRIPTION OF MATERIAL CHANGE

See the attached news release.

# 6. RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not applicable.

# 7. OMITTED INFORMATION

Not applicable.

# 8. EXECUTIVE OFFICER – FOR FURTHER INFORMATION CONTACT:

For further information, please contact Steven T. Guillen, Chief Executive Officer of the Company, at (905) 670-4428.

**DATED** at Mississauga this 12<sup>th</sup> day of April, 2013.

MEDX HEALTH CORP.

Per: *"Steven T. Guillen"* Name: Steven T. Guillen Title: Chief Executive Officer



For Immediate Release

HEALTH

# MEDX HEALTH CORP.

**NEWS RELEASE** 

TSX Venture Symbol: MDX

CUSIP #: 585090

April 12, 2013

#### For Immediate Release

# MedX announces anticipated delay in Annual Financial Results for the year ended December 31, 2012

Mississauga, Ontario.- MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX). As a result of delays in being able to obtain funding to secure fees due to its auditors, which funding has now been secured, the Company anticipates that it will be unable to meet its originally scheduled filing of the annual audited consolidated financial statements for the year ended December 31, 2012, the Management's Discussion and Analysis for the for the year and relevant CEO and CFO Certifications within the time prescribed by securities regulations, namely April 30, 2013. Management has taken steps to resolve the difficulties, and believes that as a result it will be able to file the annual audited consolidated financial statements, MD&A and CEO and CFO Certifications for the year ended December 31, 2012, by May 17, 2013.

The Company has made an application to the Ontario Securities Commission, as its Principal Regulator, for issuance of a Management Cease Trade Order pursuant to National Policy 12-203, and intends to comply with its obligations to satisfy the provisions of the alternative information guidelines as set out in National Policy 12-203 for so long as it remains in default

MedX is not the subject of any insolvency proceeding.

There is no other material information that has not been generally disclosed.

#### About MedX Health Corp.

MedX is a global leader in the development, manufacture and distribution of leading edge quality patented optical biopsy technology used in early diagnosis of skin cancer and low level laser light technology for use in numerous medical settings for tissue repair including rehab/sports medicine, dentistry, wound care, and pain management.

This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

For further information, please contact Steve Guillen, Chief Executive Officer at (905) 670-4428 Email inquiries should be made to: Steve.Guillen@medxhealth.com and the company website is located at



www.medxhealth.com. Inquiries by direct mail should be addressed to; MedX Health Corp. 220 Superior Blvd., Mississauga, Ontario, L5T 2L2

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set out in this News Release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of MDX as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Although MDX believes that the expectations reflected in the forward-looking statements set out in this press release or incorporated herein by reference are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of MDX contained in this News Release, or incorporated herein by reference, are expressly qualified, in their entirety, by this cautionary statement and the risk factors contained in MDX's current annual information form available at www.sedar.com